Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

Shares of San Francisco-based genetic testing and data company Invitae Corporation (NVTA) exploded higher after reporting earnings Tuesday night. After 6.5 trading hours on Wednesday, Invitae stock ...

Within the last quarter, Invitae (NYSE:NVTA) has observed the following analyst ratings: These 5 analysts have an average price target of $7.2 versus the current price of Invitae at $2.675, implying ...

Invitae Corporation faces significant challenges in addressing its liquidity concerns. Invitae has entered into an Asset Purchase Agreement with Natera, involving the sale of specific assets in the ...

Invitae's shares have plummeted as the company slashed its growth forecast to avoid bankruptcy. Revenue for Q2 was slightly above estimates but down 12% YoY, and analyst revenue estimates have ...

In the latest trading session, Invitae (NVTA) closed at $29.95, marking a +1.66% move from the previous day. This change outpaced the S&P 500's 0.74% gain on the day. Coming into today, shares of the ...